Most investors would like a "do over."

They look back on certain investments and wish they'd never heard of, much less put money in them. Sure things like your good friend's invention that would make beer in one day from water and weeds. Or your brother's idea of selling real estate on Saturn. Everyone has their own stories. Mine are usually related to private investments in the medical device field or biotech, though I did have one out of Florida that made a "pig" that ran through oil pipelines to check on their safety. After meeting the founder who looked more like a used car salesman that caught a great sale on polyester suits, I should have known better right then. But I didn't.

Continue reading Comfort Zone Investing: If I Could Start All Over Again ...

Comfort Zone Investing: If I Could Start All Over Again ... originally appeared on BloggingStocks on Sat, 02 Apr 2011 10:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Polo Ralph Lauren (RL) to buy from hold at Citigroup.
• Qualcomm (QCOM) to buy from neutral at Roth Capital.
• Walgreen (WAG) to conviction buy from neutral at Goldman.
• Rockwell (ROK) to outperform from neutral at Credit Suisse.
• Carnival (CCL) to buy from hold at Deutsche Bank.
• SunTrust (STI) and TD Bank (TD) to outperform from market perform at Keefe Bruyette.
• Hawaiian Electric (HE) to outperform from neutral at RW Baird.
• Essex Property Trust (ESS) to outperform from neutral at Macquarie.
• Amgen (AMGN) to neutral from underperform at BofA/Merrill.

Continue reading Analyst Calls: EBAY, ERIC, MMI, MSI, NKE, QCOM, RL, ROK, SWY, WAG ...

Analyst Calls: EBAY, ERIC, MMI, MSI, NKE, QCOM, RL, ROK, SWY, WAG ... originally appeared on BloggingStocks on Tue, 04 Jan 2011 11:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: FOMC Meets Equity Unease (AMGN, BBY, BP, GXDX, OXPS, VECO)

Closing Bell: FOMC Meets Equity Unease (AMGN, BBY, BP, GXDX, OXPS, VECO) originally appeared on BloggingStocks on Tue, 14 Dec 2010 16:20:00 EST. Please see our terms for use of feeds.

Late Monday, Amgen (AMGN) unveiled positive results for its bone drug, denosumab. A clinical study of 1,432 men with hormone refractory prostate cancer revealed that denosumab, which is also known as Xgeva, improved bone metastasis-free survival by 4.2 months. However, the overall survival rate was comparable to a placebo group.

Denosumab is already used to treat osteoporosis under the brand name Prolia, and has been approved under the brand name Xgeva for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. The drug has not yet been approved for the prevention of SREs in multiple myeloma patients.

Continue reading Amgen Boosted by Upbeat Drug Data

Amgen Boosted by Upbeat Drug Data originally appeared on BloggingStocks on Tue, 14 Dec 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Amgen (AMGN) to overweight from neutral at Piper Jaffray.
• Goodrich Petroleum (GDP) to outperform from market perform at Wells Fargo.
• Tutor Perini (TPC) to buy from neutral at UBS.
• Covidien (COV) to buy from neutral at Goldman.
• Sara Lee (SLE) and Comcast (CMCSA) to outperform from market perform at Bernstein.
• Research In Motion (RIMM) to outperform from sector perform at FBN Securities.

Continue reading Analyst Calls: AMGN, CMCSA, GDP, FAST, FLR, KBR, PGR, RIMM, SLE, WAG ...

Analyst Calls: AMGN, CMCSA, GDP, FAST, FLR, KBR, PGR, RIMM, SLE, WAG ... originally appeared on BloggingStocks on Tue, 14 Dec 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
• Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
• Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
• Citigroup upgraded Kimco Realty (KIM) to hold from sell.
• Mistras (MG) was upgraded to buy from hold at KeyBanc.
• Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
• Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.

Continue reading Analyst Calls: AAPL, AMGN, BIIB, BSX, CHK, DVN, EOG, GRMN, PHM, WPO ...

Analyst Calls: AAPL, AMGN, BIIB, BSX, CHK, DVN, EOG, GRMN, PHM, WPO ... originally appeared on BloggingStocks on Thu, 04 Nov 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Soleil upgraded Hologic (HOLX) to buy from hold on expectations the company's next-generation breast tomosynthesis instrument is likely to receive FDA approval. The firm raised its target price for shares to $20 from $16.
• ING Group upgraded Total (TOT) to buy from hold.
• BofA/Merrill raised Medicis (MRX) to neutral from underperform.
• CPFL Energia (CPL) was upgraded to buy from hold at Deutsche Bank.

Continue reading Analyst Calls: AMGN, ARST, CPB, FE, GMAN, HOLX, NWL, TOT, XOM ...

Analyst Calls: AMGN, ARST, CPB, FE, GMAN, HOLX, NWL, TOT, XOM ... originally appeared on BloggingStocks on Tue, 14 Sep 2010 12:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
• Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
• Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
• BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
• Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
• Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
• Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.

Continue reading Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ...

Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ... originally appeared on BloggingStocks on Thu, 09 Sep 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
• ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
• Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
• Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
• MedAssets (MDAS) was upgraded to buy from hold at Auriga.
• Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.

Continue reading Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ...

Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ... originally appeared on BloggingStocks on Mon, 16 Aug 2010 11:30:00 EST. Please see our terms for use of feeds.

Continue reading Amgen Posts Better-Than-Expected Q2 Earnings

Amgen Posts Better-Than-Expected Q2 Earnings originally appeared on BloggingStocks on Thu, 29 Jul 2010 17:00:00 EST. Please see our terms for use of feeds.

Continue reading Three Health Care Stocks to Sell: Amgen, Baxter, Becton Dickinson

Three Health Care Stocks to Sell: Amgen, Baxter, Becton Dickinson originally appeared on BloggingStocks on Thu, 22 Jul 2010 14:30:00 EST. Please see our terms for use of feeds.

Continue reading Amgen's Demosumab gets Priority FDA Review

Amgen's Demosumab gets Priority FDA Review originally appeared on BloggingStocks on Mon, 19 Jul 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading E*TRADE, Amgen and Others Heating Up in Google Searches

E*TRADE, Amgen and Others Heating Up in Google Searches originally appeared on BloggingStocks on Thu, 03 Jun 2010 17:30:00 EST. Please see our terms for use of feeds.

Continue reading Amgen Gets Quick FDA Approval for Osteoporosis Treatment

Amgen Gets Quick FDA Approval for Osteoporosis Treatment originally appeared on BloggingStocks on Wed, 02 Jun 2010 14:00:00 EST. Please see our terms for use of feeds.

A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.

It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.

Continue reading Deadbeat Stock #6: Amgen (AMGN)

Deadbeat Stock #6: Amgen (AMGN) originally appeared on BloggingStocks on Sun, 21 Mar 2010 13:00:00 EST. Please see our terms for use of feeds.

Spring is finally here, which means it's time to break out the broom and dustpan for some spring cleaning.

But your home isn't the only thing that requires constant maintenance -- your portfolio does too.

And what better time than spring to get a fresh start by cleaning out the stocks that are sitting around collecting dust rather than making you money?

Continue reading Six Deadbeat Stocks to Clean Out of Your Portfolio

Six Deadbeat Stocks to Clean Out of Your Portfolio originally appeared on BloggingStocks on Sat, 20 Mar 2010 09:00:00 EST. Please see our terms for use of feeds.

Apparently, AMGN's confidence is not contagious, with the stock trading fractionally lower at last check. In fact, the stock is now hovering below short-term support from its 10-day moving average, which has been breached only once on a daily closing basis since early November.

Continue reading Amgen draws skeptical option trade after hiking buyback program

Amgen draws skeptical option trade after hiking buyback program originally appeared on BloggingStocks on Mon, 07 Dec 2009 13:40:00 EST. Please see our terms for use of feeds.

Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money. Cures for all types of cancers always seem imminent with promising (there's that word again) results from mice or small control groups. Phase I testing is completed and all kinds of good stuff seems possible. Then something usually happens. Usually not very good things.

Most of the time, it's discovered that what works in mice doesn't work in men (or women). Or that the group was too small for meaningful data and when a larger group is studied, the efficacy isn't there. Or as soon as there's a bounce in the stock price, much more stock is issued and dilution occurs.

Continue reading Comfort Zone Investing: Beware pretty promises when buying biotechs

Comfort Zone Investing: Beware pretty promises when buying biotechs originally appeared on BloggingStocks on Sat, 15 Aug 2009 10:30:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Baird upgraded Tenet Healthcare (NYSE: THC) to Outperform from Neutral and raised its target to $6 from $5 based on cost trends, valuation, and expectations the company can beat expectations over the next six months.
• Oppenheimer upgraded E-House (NYSE: EJ) to Outperform from Perform following the company's better-than-expected Q2 results. The firm has a price target of $27 on shares.
• JPMorgan upgraded Avery Dennison (NYSE: AVY) to Overweight from Neutral and has a $33 target on the stock. The firm cites valuation for the upgrade following the recent underperformance and expects the company's margins to expand as demand rebounds.
• Citigroup (NYSE: C) was upgraded to Buy from Underperform at BofA/Merrill.
• Taubman Centers (NYSE: TCO) was upgraded to Conviction Buy from Buy at Goldman.
• First Niagara (NASDAQ: FNFG) was upgraded to Buy from Neutral at Janney Montgomery.

Continue reading Analyst upgrades, downgrades and initiations: AMGN, AVY, C, FMCN, THC ...

Analyst upgrades, downgrades and initiations: AMGN, AVY, C, FMCN, THC ... originally appeared on BloggingStocks on Fri, 14 Aug 2009 11:30:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Citigroup upgraded Brightpoint (NASDAQ: CELL) to Buy from Hold on expectations global handset units will trough in 2009, leading to a higher multiple for the stock. Citi raised its target on shares to $9 from $6.50.
• FBR Capital upgraded Rosetta Resources (NASDAQ: ROSE) to Outperform from Market Perform on valuation and believes drilling results in Q3 and Q4 should serve as near-term catalysts. The firm raised its target on shares to $15.
• Piper Jaffray upgraded Echelon (NASDAQ: ELON) to Neutral from Underweight following the company's contract announcement with Duke Energy (NYSE: DUK). The firm raised its target on shares to $10 from $6.
• Smith & Nephew (NYSE: SNN) was upgraded to Equal Weight from Underweight at Morgan Stanley.
• Schawk (NYSE: SGK) was upgraded to Neutral from Underperform at Baird.
• Alpha Natural (NYSE: ANR) was upgraded to Outperform from Market Perform at BMO Capital.

Continue reading Analyst upgrades, downgrades and initiations: AMGN, KR, ROSE, SWY, YUM ...

Analyst upgrades, downgrades and initiations: AMGN, KR, ROSE, SWY, YUM ... originally appeared on BloggingStocks on Tue, 11 Aug 2009 11:10:00 EST. Please see our terms for use of feeds.